150 related articles for article (PubMed ID: 35469666)
1. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI.
Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D
Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract][Full Text] [Related]
3. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
[TBL] [Abstract][Full Text] [Related]
4. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
5. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
Lu J; Li X; Li H
Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
[TBL] [Abstract][Full Text] [Related]
6. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
7. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
[TBL] [Abstract][Full Text] [Related]
8. Correlation between dynamic susceptibility contrast perfusion MRI and genomic alterations in glioblastoma.
Ozturk K; Soylu E; Cayci Z
Neuroradiology; 2021 Nov; 63(11):1801-1810. PubMed ID: 33738509
[TBL] [Abstract][Full Text] [Related]
9. Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.
Ryoo I; Choi SH; Kim JH; Sohn CH; Kim SC; Shin HS; Yeom JA; Jung SC; Lee AL; Yun TJ; Park CK; Park SH
PLoS One; 2013; 8(8):e71704. PubMed ID: 23977117
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Assessment of
Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
[TBL] [Abstract][Full Text] [Related]
11.
Choi HJ; Choi SH; You SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park CK; Park SH
AJNR Am J Neuroradiol; 2021 May; 42(5):853-860. PubMed ID: 33632732
[TBL] [Abstract][Full Text] [Related]
12. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
13. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
Crisi G; Filice S
J Neuroimaging; 2020 Jul; 30(4):458-462. PubMed ID: 32374045
[TBL] [Abstract][Full Text] [Related]
14. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
15. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
16. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
[TBL] [Abstract][Full Text] [Related]
17. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
[TBL] [Abstract][Full Text] [Related]
18. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
19. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
Lin Y; Xing Z; She D; Yang X; Zheng Y; Xiao Z; Wang X; Cao D
Neuroradiology; 2017 Jun; 59(6):555-562. PubMed ID: 28474187
[TBL] [Abstract][Full Text] [Related]
20. Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
Fudaba H; Momii Y; Matsuta H; Onishi K; Kawasaki Y; Sugita K; Shimomura T; Fujiki M
World Neurosurg; 2021 May; 149():e469-e480. PubMed ID: 33567368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
